Grail Shares Plunge 34% in February Amid Clinical Trial Delays, Potential Buying Opportunity Emerge

Grail Inc. (GRAL) experienced a sharp 34% decline in its share price during February 2026, marking one of the steepest single-month drops in the biotech sector that month. The sell-off followed the company’s announcement that the completion of its Phase III trial for the Galleri test had been pushed back by six months, citing logistical challenges in patient enrollment across U.S. and European sites. This delay disrupted previously anticipated timelines for FDA submission, which had been targeted for Q3 2026. The clinical delay comes at a time when Grail’s valuation had already been pressured by limited commercial rollout data and cautious payer reimbursement pathways. Despite generating $18 million in quarterly product revenue in Q4 2025, the company continues to operate at a net loss of $82 million for the same period, reflecting high R&D expenditures. These financials, combined with the trial setback, triggered investor concern about capital efficiency and time-to-market risks. Analysts note that the current market capitalization of $3.8 billion represents a 41% discount to the company’s last pre-trial delay valuation. With a total addressable market for multi-cancer screening estimated at $42 billion by 2030, and Galleri receiving breakthrough device designation from the FDA in 2024, long-term fundamentals remain intact. Several institutional investors have initiated or increased positions in February, citing the current price as a structural opportunity. The upcoming regulatory filing, expected in October 2026, will be a key catalyst. If approved, Galleri could capture a significant share of early-stage cancer diagnostics, particularly in high-risk populations. Meanwhile, the company has begun pilot programs with two major U.S. health systems, aiming to demonstrate real-world cost savings and early detection efficacy.